Comparative study on formulation and evaluation of fast dissolving Glibenclamide tablets: Opportunity in drug delivery system
Glibenclamide Tablets are used to lower blood sugar levels and are used in the treatment of late-onset diabetes (type II diabetes mellitus) in patients whose blood sugar is not controlled by diet alone and who are not suitable for insulin injections. The present work involves the formulation develop...
Saved in:
Published in | The pharma innovation Vol. 7; no. 5, Part E; p. 333 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
New Delhi
The Pharma Innovation
01.05.2018
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Glibenclamide Tablets are used to lower blood sugar levels and are used in the treatment of late-onset diabetes (type II diabetes mellitus) in patients whose blood sugar is not controlled by diet alone and who are not suitable for insulin injections. The present work involves the formulation development, optimization and in-vitro evaluation of fast dissolving tablet containing Glibenclamide. All formulations were evaluated for characteristics such as hardness, friability, disintegration time and Dissolution rate. An effective, pleasant tasting formulation was found to have a good hardness of 3 kg/cm2, disintegration time of 27+1 seconds and in vitro drug release of not less than 95% within 30 minutes. The drug release was found to be comparable with the marketed dispersible tablet. our drug meets all the criteria mentioned above. specially formulation 5 is best among all the formulations. The purpose of above study was to develop tablet of Glibenclamide using direct compression technique. The tablets were prepared using lactose and magnesium stearate with two different level of disintegrant. The super-disintegrant used in the study was starch. The total five formulations were evaluated for weight variation, thickness, hardness, friability, content of uniformity, disintegration time and dissolution characteristics |
---|---|
AbstractList | Glibenclamide Tablets are used to lower blood sugar levels and are used in the treatment of late-onset diabetes (type II diabetes mellitus) in patients whose blood sugar is not controlled by diet alone and who are not suitable for insulin injections. The present work involves the formulation development, optimization and in-vitro evaluation of fast dissolving tablet containing Glibenclamide. All formulations were evaluated for characteristics such as hardness, friability, disintegration time and Dissolution rate. An effective, pleasant tasting formulation was found to have a good hardness of 3 kg/cm2, disintegration time of 27+1 seconds and in vitro drug release of not less than 95% within 30 minutes. The drug release was found to be comparable with the marketed dispersible tablet. our drug meets all the criteria mentioned above. specially formulation 5 is best among all the formulations. The purpose of above study was to develop tablet of Glibenclamide using direct compression technique. The tablets were prepared using lactose and magnesium stearate with two different level of disintegrant. The super-disintegrant used in the study was starch. The total five formulations were evaluated for weight variation, thickness, hardness, friability, content of uniformity, disintegration time and dissolution characteristics |
Author | Akhter, Shammi Hasan, Md Mehdi Hassan, Mahmud Reza Simom Hasan |
Author_xml | – sequence: 1 givenname: Shammi surname: Akhter fullname: Akhter, Shammi – sequence: 2 fullname: Simom Hasan – sequence: 3 givenname: Md surname: Hasan middlename: Mehdi fullname: Hasan, Md Mehdi – sequence: 4 givenname: Mahmud surname: Hassan middlename: Reza fullname: Hassan, Mahmud Reza |
BookMark | eNqNTU1LAzEQDUWhVfsfBjwXSlJd4rVovXnxXlIzW1KyM2tmsrAH_3sD-gN8l_cJ787cEBMuzMrartt0z_5padYil22D985ZvzI_ex7GUIKmCUG0xhmYoOcy1NzCpgNFwCnk-mu5hz6IQkwinKdEZzjkdEL6ymFIEUHDKaPKC3yMIxetlHSGRBBLPUPE3I7KDDKL4vBgbvuQBdd_fG8e314_9--bsfB3RdHjhWuhVh3tdmc77_zOuf-trt_nUxg |
ContentType | Journal Article |
Copyright | Copyright The Pharma Innovation May 2018 |
Copyright_xml | – notice: Copyright The Pharma Innovation May 2018 |
DBID | 04Q 04S 04W 3V. 7X7 7XB 8AO 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH K9. M0S PQEST PQQKQ PQUKI |
DatabaseName | India Database India Database: Business India Database: Science & Technology ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) ProQuest Pharma Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni Edition) ProQuest Central UK/Ireland ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition |
DatabaseTitle | ProQuest Indian Journals ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Pharma Collection ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Indian Journals: Business Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) Indian Journals: Science & Technology ProQuest One Academic ProQuest Central (Alumni) |
DatabaseTitleList | ProQuest Indian Journals |
Database_xml | – sequence: 1 dbid: 7X7 name: ProQuest_Health & Medical Collection url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
EISSN | 2277-7695 |
GroupedDBID | 04Q 04S 04W 3V. 7X7 7XB 8AO 8FI 8FJ 8FK ABUWG ADBBV AFKRA ALMA_UNASSIGNED_HOLDINGS BENPR BPHCQ BVXVI CCPQU FYUFA HMCUK K9. OK1 PQEST PQQKQ PQUKI PROAC UKHRP |
ID | FETCH-proquest_journals_20427939433 |
IEDL.DBID | 7X7 |
IngestDate | Fri Sep 13 04:45:35 EDT 2024 |
IsPeerReviewed | false |
IsScholarly | true |
Issue | 5, Part E |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-proquest_journals_20427939433 |
PQID | 2042793943 |
PQPubID | 1176347 |
ParticipantIDs | proquest_journals_2042793943 |
PublicationCentury | 2000 |
PublicationDate | 20180501 |
PublicationDateYYYYMMDD | 2018-05-01 |
PublicationDate_xml | – month: 05 year: 2018 text: 20180501 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | New Delhi |
PublicationPlace_xml | – name: New Delhi |
PublicationTitle | The pharma innovation |
PublicationYear | 2018 |
Publisher | The Pharma Innovation |
Publisher_xml | – name: The Pharma Innovation |
SSID | ssj0000993329 |
Score | 4.143929 |
Snippet | Glibenclamide Tablets are used to lower blood sugar levels and are used in the treatment of late-onset diabetes (type II diabetes mellitus) in patients whose... |
SourceID | proquest |
SourceType | Aggregation Database |
StartPage | 333 |
SubjectTerms | Diabetes |
Title | Comparative study on formulation and evaluation of fast dissolving Glibenclamide tablets: Opportunity in drug delivery system |
URI | https://www.proquest.com/docview/2042793943/abstract/ |
Volume | 7 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LS8NAEB5qe_EiioqPWgb0Gko2u03iRbS0FsEqopBb2UcihZLUJj304H93p0mMXnpeWJaZ2Zlv3gA3TDAudaKdgPnM4XqgHBkYQQ3M0tprzUVIDc7P08Hkgz9FImrBpO6FobLKWiduFbXJNMXIrZPOmZWlkHt9qSgKoIv-3fLLof1RlGetlmnsQcdlFlZYyfYj_zfaYnGQ5_2DkX-syPgQDir4h_clv46gFafH8D1sRnDjdt4rZikSmqx2a6F197GZy41ZgonMC6RkeragkAA-Up1Iqi1_5ybGghqiivwWX5aEr9f2325wnqJZrT_RxAsqxthgOcX5BK7Ho_fhxKnfPKvkK5811PBOoZ1maXwGGAqT-IFylWAhN0GsjGSu4p40iWf9FHEO3V03Xew-voR9CxaCstivC-1itY6vrEEuVG9L6x50HkbT17cfDSyZvg |
link.rule.ids | 315,786,790,12083,21416,31754,33779,43345,43840 |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV07T8NADLagDLAgECAeBSzBmqH3aBIWhCpKgLYsRcoWJbkLqlQlbZMMHfjvnJOUwNL5pNPpzmd_tj_bAPdMMhHGSWw5zGaWiPuRFTpKUgFzaOx1LKRLBc7jSd_7FG--9JuAW97QKjc6sVLUKospRm6cdMGMLLmCPy6WFk2NouxqM0JjF_YE54IofbZv_8ZYDPrh_B94_GM7hkdw2IA-fKpf6Rh2dHoC34O28TZWXV4xS5EwZDNRC42Tj203bswSTMK8QEqhZ3MKBOALsUPS2LzqTGksqAyqyB_wY0GoujS_dY2zFNWq_EKl50TBWGPdu_kU7obP04Fnbc4cNFKVB-0d8DPopFmqzwFdqRLbiXqRZK5Qjo5UyHqR4KFKuPFO5AV0t-10uX35Fva96XgUjF4n71dwYOCCU9P9utApVqW-Nia5iG6qe_8BdGWXVw |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Comparative+study+on+formulation+and+evaluation+of+fast+dissolving+Glibenclamide+tablets%3A+Opportunity+in+drug+delivery+system&rft.jtitle=The+pharma+innovation&rft.au=Akhter%2C+Shammi&rft.au=Simom+Hasan&rft.au=Hasan%2C+Md+Mehdi&rft.au=Hassan%2C+Mahmud+Reza&rft.date=2018-05-01&rft.pub=The+Pharma+Innovation&rft.eissn=2277-7695&rft.volume=7&rft.issue=5%2C+Part+E&rft.spage=333 |